Blog

Major investors, spooked by AI exuberance yet wary of betting against it, are shifting from hyped-up stocks into potential next-in-line winners, reviving a strategy from the 1990s dotcom era that helped some sidestep the crash.

As U.S. stocks have hit successive records and AI chipmaker Nvidia’s valuation has surged beyond $4 trillion, professional investors have been trying to find ways to make money from the bull market while avoiding excessive risk.

Some are looking back to the 1990s internet boom, which spread from startups to telecoms and tech, and where hedge funds rode the wave by flipping out of highly-valued stocks before they peaked and picking others that had room to rise.

“What we are doing is what worked from 1998 to 2000,” said Francesco Sandrini, multi-asset head and Italy CIO at Europe’s largest asset manager Amundi.

He highlighted signs of irrational exuberance on Wall Street, such as frenzied trading in risky options pegged to the share prices of big AI stocks. But he said he expected the new tech enthusiasm to continue and hoped to bank gains via bets on reasonably valued assets that might rally next.

Sandrini said this involved trying to find “the highest growth opportunities that so far the market had failed to spot”, with moves into software groups, robotics and Asian tech.

Other investors also expected to edge out of Wall Street’s Magnificent Seven stocks after shares in Nvidia more than tripled in two years, but want to keep their diversification within the AI sphere.

ASSET MANAGERS NEED TO BE NIMBLE TO RIDE THE WAVE

“The odds of this (AI boom) being a bust are very high because you’ve got companies spending trillions and all fighting for the same market that does not yet exist,” said Goshawk Asset Management CIO Simon Edelsten, who worked on telecom IPOs at stockbroker Dresdner Kleinwort Benson in London in 1999.

He expected the next phase of AI fever to spread from Nvidia and others like Microsoft and Alphabet into
related sectors.

Timing the phases of a bubble has historically been a way to play it without the risk of trying to call the peak too early.

A study by economists Markus Brunnermeir and Stefan Nagel showed that hedge funds mostly did not bet against the dotcom bubble, but rode it skillfully enough to beat the market by about 4.5% per quarter from 1998-2000 and avoid the worst of the downturn.

They shed high-priced internet stocks in time to recycle profits into others before they caught the attention of less sophisticated investors.

“There were good profits to be made for the fleet of foot even during 2000 when the top came,” Edelsten at Goshawk said, adding the current market environment was similar to 1999.

He favoured IT consultants and Japanese robotics groups that can potentially pick up revenues from AI heavyweights, in what he said was the typical chronology of a market gold rush.

“When someone strikes gold, (you) buy the local hardware store where the prospectors will buy all their shovels.”

INVESTORS TRY TO STAY IN AI WITHOUT EXCESSIVE RISK

Investors are also attempting to benefit from the trillion of dollars so-called hyperscalers such as Amazon, Microsoft and Alphabet are committing to AI data centres and advanced chips without taking on more direct exposure to these companies.

Fidelity International multi-asset manager Becky Qin said uranium was her favoured new AI trade because power-hungry AI data centres could gobble up nuclear energy.

Kevin Thozet, investment committee member at asset manager Carmignac, was taking profits on Magnificent Seven stocks and building up a position in Taiwan’s Gudeng Precision, which makes delivery boxes for AI chipmakers including TSMC.

Asset managers are also concerned that the rush to build data centres could result in overcapacity, as in the fiber-optic cable boom in the telecoms industry.

“In any new technological paradigm we don’t get from A to B without excesses along the way,” said Pictet Asset Management senior multi-asset strategist Arun Sai.

Even though top AI stocks like Microsoft, Amazon, and Alphabet are being powered by strong earnings, he still sees “the building blocks of a bubble” and favours Chinese stocks as a hedge if rapid AI advancements in China sap Wall Street’s AI enthusiasm.

Some investors, though, do not favour this relative value approach to AI investing as a way to mitigate future losses.

Oliver Blackbourn, portfolio manager at Janus Henderson, said he was hedging his U.S. tech positions with European and healthcare assets lest an AI stock crash takes the U.S. economy down with it.

He said it was impossible to forecast how long the AI craze would roll on because calling the peak was usually only possible with hindsight.

“We’re in 1999 until the bubble pops.”

Published – October 25, 2025 09:55 am IST

Story Continues

• Earlier this week, Zimmer Biomet Holdings showcased its latest orthopedic robotics and digital health innovations, including FDA-cleared mBos TKA System and the recently acquired Monogram Technologies robotic platform, at the annual meeting of the American Association of Hip and Knee Surgeons.

• A standout revelation was the integration of AI-driven and autonomous technologies into the company’s expanding knee and hip portfolios, reflecting Zimmer Biomet’s commitment to advancing surgical precision and connected care solutions.

• We’ll examine how Zimmer Biomet’s integration of AI-driven orthopedic robotics could reshape the long-term outlook for its investment narrative.

Trump has pledged to “unleash” American oil and gas and these 22 US stocks have developments that are poised to benefit.

To be a shareholder in Zimmer Biomet, you need to believe in the power of innovation in orthopedic robotics and digital health to drive demand for advanced surgical solutions. This week’s showcase of FDA-cleared and AI-powered products could energize sentiment but is unlikely to meaningfully shift the company’s near-term reliance on successful product launches; ongoing industry pricing pressures still remain the key headwind.

Among the latest announcements, the FDA clearance of the mBos TKA System stands out for its relevance, as it highlights Zimmer Biomet’s efforts to keep pace in the competitive race for autonomous robotics and supports the company’s narrative of product-driven growth, even as full regulatory approvals for other key technologies remain pending.

In contrast, investors should be aware of increasing pricing pressures and the consequences if these persist through…

Read the full narrative on Zimmer Biomet Holdings (it’s free!)

Zimmer Biomet Holdings is projected to reach $9.2 billion in revenue and $1.3 billion in earnings by 2028. This outlook assumes a 5.5% annual revenue growth rate and an earnings increase of about $476 million from the current $823.5 million.

Uncover how Zimmer Biomet Holdings’ forecasts yield a $110.92 fair value, a 8% upside to its current price.

Simply Wall St Community members estimate fair value for Zimmer Biomet anywhere between US$95 and US$167.48 per share, with three unique perspectives. As these opinions range widely, consider the risk of ongoing pricing pressures that could challenge margin recovery and ultimately affect future earnings.

Explore 3 other fair value estimates on Zimmer Biomet Holdings – why the stock might be worth 8% less than the current price!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ZBH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com